PROTECT试验结果显示,在研究终点Teplizumab治疗组的C肽水平显著高于安慰剂组,平均高出0.13 pmol/mL。Teplizumab组94.9%的受试者能够维持C肽峰值水平≥0.2 pmol/mL,而安慰剂组为79.2%(p<0.001…
发布时间:2023-10-18浏览数:1k+
Stage 1 is defined as the presence of β-cell autoimmunity as evidenced by the presence of two or more islet autoantibodies with normoglycemia and is presymptomatic, stage 2 as the …
发布时间:2015-12-01浏览数:438
1型糖尿病(T1DM)分期标准不仅为临床实践也为T1DM预防药物,如抗CD3抗体药物的开发提供了重要的理论依据。
发布时间:2015-12-01浏览数:534
横切线®为注册商标
Copyright 2020 横切线®药研苑 备案号:粤ICP备18041379号-3